Mark Di Cioccio
Head of QA
As a senior consultant, Mark focuses on project management and development of medical devices, from early stage technical…
Senior Engineering Consultant
As a specialist in early stage prototypes, Joe has responsibility for the design and implementation of testing proof of…
Today we have released feasibility test results for our innovative Occoris® inhaler engine concept, demonstrating a significant improvement in the efficiency of drug delivery to the deep lung compared to typical dry powder inhaler (DPI) devices.
Team Consulting has been awarded a feasibility grant by the Technology Strategy Board, the UK’s innovation agency, to further test the commercial manufacturability of its innovative Occoris™ inhaler ‘engine’ technology. Team’s Occoris technology could potentially open up a wide range of new opportunities in the pulmonary drug delivery sector beyond the traditional asthma and COPD market.
Some 600 delegates braved the heat of the Arizona desert to attend the...
A new Dry Powder Inhaler (DPI), designed and developed by Valois Pharma with the support of Team Consulting, was presented for the first time at the recent Drug Delivery to the Lungs Conference in Edinburgh. Whilst offering excellent delivery performance, the Prohaler™ was designed from the outset with the user in mind and is completely intuitive to use.
Team Consulting and Valois Pharmaceutical Division today announced they have embarked upon a major development programme to produce a novel breath-actuated multi-dose Dry Powder Inhaler (DPI).
The 'Bead Inhaler' will utilise a unique dispersion technology proven to deliver excellent aerosolisation performance, reproducible emitted dose and high fine particle fraction. A novel drug storage and release technology is also being developed. In addition to offering excellent delivery performance and moisture protection with a wide range of formulations, the inhaler will be compact and simple to use.